ZNA,
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
verhaegen, ann
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed
4
282
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
07/24
08/24
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SERENA, NCT05569772: Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

Recruiting
3
252
Europe
Semaglutide Pen Injector, Ozempic, Semaglutide placebo
Universitaire Ziekenhuizen KU Leuven, University Hospital, Antwerp, Universitair Ziekenhuis Brussel, General Hospital Groeninge, Onze Lieve Vrouw Hospital, Jessa Hospital, Ziekenhuis Netwerk Antwerpen (ZNA), Vitaz, Centre Hospitalier Universitaire de Liege, Erasme University Hospital, Centre Hospitalier Mouscron, Jan Yperman Ziekenhuis, AZ Turnhout, AZ St- Jan Brugge
Glucose Intolerance After a Recent History of Gestational Diabetes
07/28
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
verhaegen, ann
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed
4
282
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
07/24
08/24
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SERENA, NCT05569772: Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

Recruiting
3
252
Europe
Semaglutide Pen Injector, Ozempic, Semaglutide placebo
Universitaire Ziekenhuizen KU Leuven, University Hospital, Antwerp, Universitair Ziekenhuis Brussel, General Hospital Groeninge, Onze Lieve Vrouw Hospital, Jessa Hospital, Ziekenhuis Netwerk Antwerpen (ZNA), Vitaz, Centre Hospitalier Universitaire de Liege, Erasme University Hospital, Centre Hospitalier Mouscron, Jan Yperman Ziekenhuis, AZ Turnhout, AZ St- Jan Brugge
Glucose Intolerance After a Recent History of Gestational Diabetes
07/28
12/28

Download Options